A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects

Schizophrenia Research

Volumn 89, Issue 1-3, 2007, Pages 211-224

  Woodward, Neil D ^a   Purdon, Scot E ^b   Meltzer, Herbert Y ^c   Zald, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Haloperidol; Meta analysis; Neuropsychology; Practice effects; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG MEGADOSE; EFFECT SIZE; HUMAN; HYPOTHESIS; LOW DRUG DOSE; MENTAL PERFORMANCE; META ANALYSIS; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PRACTICE ACT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEAT PROCEDURE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VALIDITY; VERBALIZATION;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALOPERIDOL; HUMANS; NEUROPSYCHOLOGICAL TESTS; PRACTICE (PSYCHOLOGY); PROSPECTIVE STUDIES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 33845285511     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.08.021     Document Type: Article

References (73)

1. Basso M.R., Carona F.D., Lowery N., and Axelrod B.N. Practice effects on the WAIS-III across 3- and 6-month intervals. Clin. Neuropsychol. 16 (2002) 57-63
2. Bedard M.A., Scherer H., Delorimier J., Stip E., and Lalonde P. Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. Can. J. Psychiatry 41 (1996) S21-S24
3. Bedard M.A., Scherer H., Stip E., Cohen H., Rodriguez J.P., and Richer F. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn. 43 (2000) 31-39
4. Begg C.B. Publication bias. In: Cooper H.M., and Hedges L.V. (Eds). The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York 399-409
5. Benedict R.H., and Zgaljardic D.J. Practice effects during repeated administrations of memory tests with and without alternate forms. J. Clin. Exp. Neuropsychol. 20 (1998) 339-352
6. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L., and Lieberman J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159 (2002) 1018-1028
7. Blyler C.R., and Gold J.M. Cognitive effects of conventional antipsychotics: another look. In: Sharma T., and Harvey P.D. (Eds). Cognitive Functioning in Schizophrenia: Characteristics, Correlates, and Treatment (2000), Oxford University Press 241-265
8. Buchanan R.W., Holstein C., and Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 36 (1994) 717-725
9. Carpenter W.T., and Gold J.M. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 51 (2002) 969-971
10. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 24 (2004) 192-208
11. Dikmen S.S., Heaton R.K., Grant I., and Temkin N.R. Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J. Int. Neuropsychol. Soc. 5 (1999) 346-356
12. Dunlop W.P., Cortina J.M., Vaslow J.B., and Burke M.J. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol. Methods 1 (1996) 170-177
13. Fagerlund B., Mackeprang T., Gade A., and Glenthoj B.Y. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr. 9 (2004) 364-374
14. Follmann D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 45 (1992) 769-773
15. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
16. Gelenberg A.J., Van Putten T., Lavori P.W., Wojcik J.D., Falk W.E., Marder S., Galvin-Nadeau M., Spring B., Mohs R.C., and Brotman A.W. Anticholinergic effects on memory: benztropine versus amantadine. J. Clin. Psychopharmacol. 9 (1989) 180-185
17. Gilbertson M.W., and van Kammen D.P. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia. Biol. Psychiatry 42 (1997) 585-595
18. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72 (2004) 21-28
19. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
20. Green M.F., Marshall Jr. B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., and Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am. J. Psychiatry 154 (1997) 799-804
21. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 (2000) 119-136
22. Green M.F., Marder S.R., Glynn S.M., McGurk S.R., Wirshing W.C., Wirshing D.A., Liberman R.P., and Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51 (2002) 972-978
23. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 (2001) 176-184
24. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169 (2003) 404-411
25. Harvey P.D., Rabinowitz J., Eerdekens M., and Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psychiatry 162 (2005) 1888-1895
26. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., and Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 58 (2001) 24-32
27. Heaton R.K., Temkin N., Dikmen S., Avitable N., Taylor M.J., Marcotte T.D., and Grant I. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch. Clin. Neuropsychol. 16 (2001) 75-91
28. Hedges L.V. Fixed effects models. In: Cooper H.M., and Hedges L.V. (Eds). The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York 285-300
29. Hedges L.V., and Vevea J.L. Fixed- and random-effects models in meta-analysis. Psychol. Methods 3 (1998) 486-504
30. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 (1998) 426-445
31. Hill S.K., Schuepbach D., Herbener E.S., Keshavan M.S., and Sweeney J.A. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res. 68 (2004) 49-63
32. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
33. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
34. Kasper S., and Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28 Suppl 1 (2003) 27-38
35. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Lewine R.R., Yurgelun-Todd D.A., Gur R.C., Tohen M., Tollefson G.D., Sanger T.M., and Lieberman J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161 (2004) 985-995
36. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., and Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 81 (2006) 1-15
37. Kern R.S., Green M.F., Marshall Jr. B.D., Wirshing W.C., Wirshing D., McGurk S.R., Marder S.R., and Mintz J. Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. Schizophr. Bull. 25 (1999) 223-232
38. Kumari V., Corr P.J., Mulligan O.F., Cotter P.A., Checkley S.A., and Gray J.A. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology (Berl) 129 (1997) 271-276
39. Lee M.A., Jayathilake K., and Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37 (1999) 1-11
40. Legangneux E., McEwen J., Wesnes K.A., Bergougnan L., Miget N., Canal M., L'Heritier C., Pinquier J.L., and Rosenzweig P. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J. Psychopharmacol. 14 (2000) 164-171
41. Levine A.J., Miller E.N., Becker J.T., Selnes O.A., and Cohen B.A. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin. Neuropsychol. 18 (2004) 373-384
42. Lezak M.D. Neuropsychological Assessment. 3rd ed. vol. 3 (1995), Oxford, New York
43. Liu S.K., Chen W.J., Chang C.J., and Lin H.N. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 22 (2000) 311-319
44. McCaffrey R.J., Duff K., and Westervelt H.J. Practitioner's Guide to Evaluating Change wtih Neuropsychological Assessment Instruments (2000), Kluwer Academic/ Plenum Publishers, New York
45. McGurk S., Green M.F., Wirshing W.C., Ames D.C., Marshall Jr. B.D., Marder S.R., and Mintz J.M. The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trial making test. CNS Spectr. 2 (1997) 60-64
46. McGurk S.R., Green M.F., Wirshing W.C., Wirshing D.A., Marder S.R., Mintz J., and Kern R. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr. Res. 68 (2004) 225-233
47. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr. Opin. Pharmacol. 4 (2004) 53-57
48. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25 (1999) 233-255
49. Meltzer H.Y., and Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry 53 (2003) 265-267
50. Mishara A.L., and Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry 55 (2004) 1013-1022
51. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72 (2004) 29-39
52. Petitti D.B. Approaches to heterogeneity in meta-analysis. Stat. Med. 20 (2001) 3625-3633
53. Potkin S.G., Fleming K., Jin Y., and Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol. 21 (2001) 479-483
54. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., and Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 249-258
55. Purdon S.E., Malla A., Labelle A., and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26 (2001) 137-149
56. Purdon S.E., Woodward N.D., Mintz A., and Labelle A. Procedural learning improvements after six weeks of clozapine treatment. Schizophr. Res. 53 (2002) 165-166
57. Purdon S.E., Woodward N., Lindborg S.R., and Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 169 (2003) 390-397
58. Ramaekers J.G., Louwerens J.W., Muntjewerff N.D., Milius H., de Bie A., Rosenzweig P., Patat A., and O'Hanlon J.F. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J. Clin. Psychopharmacol. 19 (1999) 209-221
59. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S., Leslie D., Allan E., Campbell E.C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L., Evans D., Frecska E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., Mena F., Sheikh J., Smelson D., and Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290 (2003) 2693-2702
60. Ruff R.M., Light R.H., Parker S.B., and Levin H.S. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch. Clin. Neuropsychol. 11 (1996) 329-338
61. Salinsky M.C., Storzbach D., Dodrill C.B., and Binder L.M. Test-retest bias, reliability, and regression equations for neuropsychological measures repeated over a 12-16-week period. J. Int. Neuropsychol. Soc. 7 (2001) 597-605
62. Shadish W.R., and Haddock C.K. Combining estimates of effect size. In: Cooper H.M., and Hedges L.V. (Eds). The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York 261-282
63. Smith R.C., Infante M., Singh A., and Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int. J. Neuropsychopharmacol. 4 (2001) 239-250
64. Spohn H.E., and Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychology 98 (1989) 367-380
65. Spreen O., and Strauss E. A Compendium of Neuropsychological Tests Administration, Norms, and Commentary. 2nd ed. (1998), Oxford University Press, New York
66. Tandon R., Milner K., and Jibson M.D. Antipsychotics from theory to practice: integrating clinical and basic data. J. Clin. Psychiatry 60 Suppl 8 (1999) 21-28
67. Temkin N.R., Heaton R.K., Grant I., and Dikmen S.S. Detecting significant change in neuropsychological test performance: a comparison of four models. J. Int. Neuropsychol. Soc. 5 (1999) 357-369
68. Velligan D.I., Newcomer J., Pultz J., Csernansky J., Hoff A.L., Mahurin R., and Miller A.L. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr. Res. 53 (2002) 239-248
69. Velligan D.I., Prihoda T.J., Sui D., Ritch J.L., Maples N., and Miller A.L. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry 64 (2003) 524-531
70. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R) (1981), The Psychological Corporation, Harcourt Brace Jovanovich, Cleveland
71. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472
72. Zachariah E., Kumari V., Galea A., Das M., Mehrotra R., Taylor D., Ruprah M., and Sharma T. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J. Clin. Psychopharmacol. 22 (2002) 224-226
73. Zgaljardic D.J., and Benedict R.H. Evaluation of practice effects in language and spatial processing test performance. Appl. Neuropsychol. 8 (2001) 218-223